Tag Archive for: life sciences

Sofinnova Partners unveils Sofinnova.AI: A cutting-edge artificial intelligence platform set to transform its life sciences investment practice

/in

Combination of real time scientific databases with proprietary data will enable venture capital firm to enhance deal origination and portfolio growth through data-driven insights and strengthened entrepreneurial partnerships   PARIS, France – December 5, 2023 –  Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the […]

Read more

Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals

/in

Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]

Read more

Brace yourself for the busiest week in biopharma!

/in

More than hangover-busting aspirin will be in order at the biopharma industry’s biggest week in London.  The capital will host a gruelling conference double header, beginning with the LSX Inv€$tival Showcase on Monday 13th November, followed by the Jefferies London Healthcare Conference on Tuesday 14th November.  With investors and biopharma business leaders descending on the […]

Read more

The ‘must-attend’ Healthcare conferences Autumn / Winter 2023

/in

It is quite astonishing just how quick time flies – so let’s look ahead to the top events coming up for Autumn / Winter 2023/24… Now really is the time to be organising your calendar for the latter half of the year, so don’t miss the early-bird discounts, and secure your travel and accommodation whilst […]

Read more

Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

/in

US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the first patient has […]

Read more